These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

482 related articles for article (PubMed ID: 36771465)

  • 21. Drug Therapies for Chronic Cholestatic Liver Diseases.
    Wagner M; Fickert P
    Annu Rev Pharmacol Toxicol; 2020 Jan; 60():503-527. PubMed ID: 31506007
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Immune-mediated cholangiopathies : Diagnostic and therapeutic challenges].
    Herta T; Beuers U
    Radiologe; 2019 Apr; 59(4):348-356. PubMed ID: 30874827
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Kinetics of hepatic bile acid handling in cholestatic liver disease: effect of ursodeoxycholic acid.
    Jazrawi RP; de Caestecker JS; Goggin PM; Britten AJ; Joseph AE; Maxwell JD; Northfield TC
    Gastroenterology; 1994 Jan; 106(1):134-42. PubMed ID: 8276175
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Treatment of cholestatic liver diseases with ursodeoxycholic acid].
    Boberg KM; Schrumpf E
    Tidsskr Nor Laegeforen; 1997 Sep; 117(23):3370-3. PubMed ID: 9411890
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Single or multiple dose ursodeoxycholic acid for cholestatic liver disease: biliary enrichment and biochemical response.
    van de Meeberg PC; Wolfhagen FH; Van Berge-Henegouwen GP; Salemans JM; Tangerman A; van Buuren HR; van Hattum J; van Erpecum KJ
    J Hepatol; 1996 Dec; 25(6):887-94. PubMed ID: 9007717
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Primary biliary cirrhosis and bile acids.
    Corpechot C
    Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S13-20. PubMed ID: 23141888
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Advances in the treatment of primary biliary cholangitis].
    Li YM; Wang QX; Ma X
    Zhonghua Gan Zang Bing Za Zhi; 2017 Nov; 25(11):805-809. PubMed ID: 29325272
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Downregulation of TGR5 (GPBAR1) in biliary epithelial cells contributes to the pathogenesis of sclerosing cholangitis.
    Reich M; Spomer L; Klindt C; Fuchs K; Stindt J; Deutschmann K; Höhne J; Liaskou E; Hov JR; Karlsen TH; Beuers U; Verheij J; Ferreira-Gonzalez S; Hirschfield G; Forbes SJ; Schramm C; Esposito I; Nierhoff D; Fickert P; Fuchs CD; Trauner M; García-Beccaria M; Gabernet G; Nahnsen S; Mallm JP; Vogel M; Schoonjans K; Lautwein T; Köhrer K; Häussinger D; Luedde T; Heikenwalder M; Keitel V
    J Hepatol; 2021 Sep; 75(3):634-646. PubMed ID: 33872692
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bile acids and intestinal microbiota in autoimmune cholestatic liver diseases.
    Li Y; Tang R; Leung PSC; Gershwin ME; Ma X
    Autoimmun Rev; 2017 Sep; 16(9):885-896. PubMed ID: 28698093
    [TBL] [Abstract][Full Text] [Related]  

  • 30. What Comes after Ursodeoxycholic Acid in Primary Biliary Cholangitis?
    Wong LL; Hegade VS; Jones DEJ
    Dig Dis; 2017; 35(4):359-366. PubMed ID: 28468009
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ursodeoxycholate inhibits mast cell activation and reverses biliary injury and fibrosis in Mdr2
    Meng F; Kennedy L; Hargrove L; Demieville J; Jones H; Madeka T; Karstens A; Chappell K; Alpini G; Sybenga A; Invernizzi P; Bernuzzi F; DeMorrow S; Francis H
    Lab Invest; 2018 Nov; 98(11):1465-1477. PubMed ID: 30143751
    [TBL] [Abstract][Full Text] [Related]  

  • 32. From pathogenesis to novel therapies in the treatment of primary biliary cholangitis.
    Ronca V; Carbone M; Bernuzzi F; Malinverno F; Mousa HS; Gershwin ME; Invernizzi P
    Expert Rev Clin Immunol; 2017 Dec; 13(12):1121-1131. PubMed ID: 28994348
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mechanism-based target therapy in primary biliary cholangitis: opportunities before liver cirrhosis?
    Yang Y; He X; Rojas M; Leung PSC; Gao L
    Front Immunol; 2023; 14():1184252. PubMed ID: 37325634
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Investigational farnesoid X receptor agonists for the treatment of primary biliary cholangitis.
    Akepati PR; Gochanour EM
    Expert Opin Investig Drugs; 2024 Jun; 33(6):627-638. PubMed ID: 38676426
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gut microbiome in primary sclerosing cholangitis: A review.
    Little R; Wine E; Kamath BM; Griffiths AM; Ricciuto A
    World J Gastroenterol; 2020 Jun; 26(21):2768-2780. PubMed ID: 32550753
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune-mediated cholangiopathies in children: the need to better understand the pathophysiology for finding the future possible treatment targets.
    Grama A; Mititelu A; Sîrbe C; Benţa G; Pop TL
    Front Immunol; 2023; 14():1206025. PubMed ID: 37928553
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis.
    Holtmeier J; Leuschner U
    Digestion; 2001; 64(3):137-50. PubMed ID: 11786661
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The gut microbial influence on cholestatic liver disease.
    Kummen M; Hov JR
    Liver Int; 2019 Jul; 39(7):1186-1196. PubMed ID: 31125502
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting bile salt homeostasis in biliary diseases.
    Trampert DC; Kunst RF; van de Graaf SFJ
    Curr Opin Gastroenterol; 2024 Mar; 40(2):62-69. PubMed ID: 38230695
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multiple therapeutic targets in rare cholestatic liver diseases: Time to redefine treatment strategies.
    Gerussi A; D'Amato D; Cristoferi L; O'Donnell SE; Carbone M; Invernizzi P
    Ann Hepatol; 2020; 19(1):5-16. PubMed ID: 31771820
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.